1. Home
  2. BCRX vs NVAX Comparison

BCRX vs NVAX Comparison

Compare BCRX & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioCryst Pharmaceuticals Inc.

BCRX

BioCryst Pharmaceuticals Inc.

HOLD

Current Price

$7.89

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$9.39

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCRX
NVAX
Founded
1986
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.1B
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
BCRX
NVAX
Price
$7.89
$9.39
Analyst Decision
Buy
Buy
Analyst Count
11
9
Target Price
★ $20.55
$14.22
AVG Volume (30 Days)
4.7M
★ 8.3M
Earning Date
11-04-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 381.40
309.76
EPS
N/A
★ N/A
Revenue
$25,186,000.00
★ $1,123,479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.71
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 64.69
52 Week Low
$6.23
$6.20
52 Week High
$11.22
$13.39

Technical Indicators

Market Signals
Indicator
BCRX
NVAX
Relative Strength Index (RSI) 42.17 38.56
Support Level $6.35 $9.12
Resistance Level $9.22 $10.48
Average True Range (ATR) 0.30 0.96
MACD 0.00 -0.37
Stochastic Oscillator 33.49 2.57

Price Performance

Historical Comparison
BCRX
NVAX

About BCRX BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: